Patent application number | Description | Published |
20080227794 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones - Compounds of formula I: | 09-18-2008 |
20080227824 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders - The present invention is directed to novel compounds of formula (I)/(II)/(III), their use in therapy and pharmaceutical compositions comprising said novel compounds. | 09-18-2008 |
20080306077 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 - Compounds of Formula I: | 12-11-2008 |
20080306088 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 - Compounds of Formula I: | 12-11-2008 |
20080312240 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists - The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: | 12-18-2008 |
20080312246 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists - The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: | 12-18-2008 |
20080318999 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators - The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 12-25-2008 |
20090012089 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators - The present invention is directed to compounds of Formula I: | 01-08-2009 |
20090023711 | Piperazines and Piperidines as Mglur5 Potentiators - Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: | 01-22-2009 |
20090054491 | Use - The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity. | 02-26-2009 |
20090069340 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders - Compounds of Formula (I), wherein R | 03-12-2009 |
20090111821 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 - The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds. | 04-30-2009 |
20090111830 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - The present invention is directed to compounds of formula I: | 04-30-2009 |
20090124578 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - Compounds in accord with Formula I: | 05-14-2009 |
20090149505 | Metabotropic Glutamate Receptor-Potentiating Isoindolones - Compounds of Formula I: | 06-11-2009 |
20090192169 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators - Compounds of Formula I: | 07-30-2009 |
20100016403 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 01-21-2010 |
20100280082 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators - Compounds of Formula (I) wherein R | 11-04-2010 |
20100317674 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones - Compounds of formula I: | 12-16-2010 |
20110053953 | AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613 - Compounds of formula I: wherein R | 03-03-2011 |
20110166155 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - The present invention is directed to compounds of formula I: | 07-07-2011 |
20140018549 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias, wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 01-16-2014 |